R&D News | pharmaphorum

News

Venture financing for UK biotechs reached a five-year high in the second quarter of the year, with more than £2 billion raised, says BIA.

News

Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.

News

Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning the programme.

News

This week's round-up of private financings in the biotech arena features AdvanCell, alongside Draig, Drug Farm, MindRank AI, and Alchemab.

News

AtaiBeckley has been snapped up by Eli Lilly in a massive $3.8bn transaction that shows psychedelic drugs are now firmly in the pharma mainstream.

News

The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia and Braveheart the latest to make their intentions known.